Association Between Baseline Disease Characteristics and Relapse-Free Survival in Patients With BRAF V600–Mutant Resected Stage III Melanoma Treated With Adjuvant Dabrafenib + Trametinib or Placebo. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 3, p. S53, 2019. DOI: 10.25251/skin.3.supp.53. Disponível em: https://skin.dermsquared.com/skin/article/view/781. Acesso em: 19 apr. 2025.